Head-to-head dispatch
LillyDirect Foundayo vs NowPatient
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.
Marked down on: Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
Desk Score
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
Marked down on: Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
LillyDirect Foundayo takes this head-to-head with the higher Desk Score, 82/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
LillyDirect Foundayo
82/100
B−
NowPatient
59/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | LillyDirect Foundayo | NowPatient |
|---|---|---|
| Semaglutide | Not disclosed | $1,349/mo (brand Wegovy) |
| Tirzepatide | Not disclosed | $1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | All 50 states | Coverage not published |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | Patients with commercial insurance who want the cheapest legal brand-name GLP-1. | Readers who want brand-name GLP-1 access without a compounded route. |
| Desk Score | 82/100B− | 59/100C |
The verdict
Desk pick — LillyDirect FoundayoLillyDirect Foundayo takes this head-to-head with the higher Desk Score, 82/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Choose LillyDirect Foundayo if…
Patients with commercial insurance who want the cheapest legal brand-name GLP-1.
Not disclosed sema · Not disclosed tirz · All 50 states
Choose NowPatient if…
Readers who want brand-name GLP-1 access without a compounded route.
$1,349/mo (brand Wegovy) sema · $1,069/mo (brand Mounjaro, promotional rate) tirz · Coverage not published
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: LillyDirect Foundayo · NowPatient.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- LillyDirect Foundayo vs CoreAge Rx
- NowPatient vs Vaylen
- LillyDirect Foundayo vs Strut Health
- NowPatient vs Ondra Health
- LillyDirect Foundayo vs Invigor Medical
- NowPatient vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.